TiGenix’s sec­ond stab at an IPO bags $36M for late-stage stem cell plans

Bel­gian biotech TiGenix has fi­nal­ly pulled off an IPO on Nas­daq. The stem cell play­er had to re­trieve an of­fer­ing that had been shelved last spring as the mar­ket proved chilly to new­com­ers.

While the mar­ket hasn’t im­proved much over the course of the year, cool­ing off con­sid­er­ably af­ter the 2013-2015 IPO boom, Tigenix low­ered its sights and made off with a $36 mil­lion raise af­ter sell­ing 2.3 mil­lion shares at 15.50 — a sig­nif­i­cant dis­count off its price on the Brus­sels ex­change.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER